Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Agile Therapeutics, Inc. (Nasdaq: AGRX) is a forward-thinking company specializing in women's healthcare. Their mission is to address the unmet health needs of today’s women by providing innovative contraceptive options. The company’s leading product, Twirla® (ethinyl estradiol and levonorgestrel transdermal system), is a once-weekly prescription contraceptive patch that offers an alternative to daily pills or longer-acting methods. Twirla employs Agile's proprietary Skinfusion® technology designed to improve patch adhesion and patient comfort.
Recently, Agile Therapeutics has reported significant financial and operational accomplishments. In the third quarter of 2023, Twirla achieved net revenue of $6.7 million, reflecting a 21% increase from the second quarter and a 122% increase year-over-year. The company projects positive cash flow from operations by the first quarter of 2024, backed by a strong gross margin that grew to 63% in the third quarter of 2023.
The company’s strategic focus includes expanding their market presence through partnerships and promotional efforts, notably targeting five key states with high reimbursement potential. Agile is also enhancing Twirla's availability through telemedicine platforms like Nurx, TwentyEight Health, and Pandia, aiming to broaden its reach further.
Operational expenses have been managed effectively, with a reported decrease in GAAP operating expenses to $8.2 million in the third quarter of 2023. This financial discipline, alongside the anticipated revenue, positions Agile Therapeutics favorably for sustainable growth.
Additionally, Agile Therapeutics has successfully completed the pay-off of their debt facility with Perceptive Advisors, leaving their balance sheet debt-free. Despite a delisting notice from Nasdaq, the company’s shares continue to trade on the OTC Market, maintaining its focus on executing its business plan and exploring strategic opportunities to maximize Twirla’s growth and shareholder value.
For more detailed updates, latest news, and information, you can visit their website at www.agiletherapeutics.com or follow them on Twitter @agilether.
Agile Therapeutics (Nasdaq: AGRX) has appointed Josephine Torrente to its board of directors, effective October 7, 2021. As a Class II director, she will serve on the Science and Technology and Nominating and Corporate Governance Committees. Torrente, who has over 30 years of experience in the pharmaceutical industry, brings regulatory expertise and strategic insights that Agile anticipates will enhance its growth trajectory. Her previous roles include Executive VP at Sprout Pharmaceuticals and extensive work at a law firm specializing in FDA matters.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced the pricing of its public offering of 26,666,648 shares of common stock and warrants for 13,333,324 shares at $0.85 per share. The expected gross proceeds are approximately $22.67 million, before expenses. The warrants are exercisable immediately at the same price and expire in five years. The offering, led by Oppenheimer & Co., is set to close around October 13, 2021, pending customary conditions. Agile continues to focus on women's healthcare, notably through its contraceptive product, Twirla.
Agile Therapeutics (Nasdaq: AGRX) announced plans for an underwritten public offering of its common stock and warrants to purchase its common stock. All shares offered will be sold by the company, with the offering dependent on market conditions. Oppenheimer & Co. Inc. is the sole book-running manager for the offering, which will be conducted under Agile's effective shelf registration statement filed with the SEC. Potential investors are encouraged to review the preliminary prospectus supplement and accompanying prospectus for detailed information.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced that the California Medicaid Program, Medi-Cal, has officially added Twirla to its preferred drug list as of October 1, 2021. This inclusion applies to approximately 15 million beneficiaries in California, initially affecting those under fee-for-service plans and expanding to other beneficiaries by January 1, 2022. CEO Al Altomari emphasized the importance of broadening access to contraceptive options and highlighted Twirla as a significant choice for women seeking low-dose estrogen contraceptives.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced a partnership with U.S. Women’s Soccer star Carli Lloyd on September 28, 2021. This collaboration aims to raise awareness about women’s health issues and promote Agile's mission in women's healthcare. Lloyd, who will play her final match for the U.S. Women’s National Team on October 26, is passionate about empowering women in their healthcare choices. Agile's first product, the contraceptive patch Twirla, was FDA-approved in February 2020, and the company has four additional contraceptive products in development.
Agile Therapeutics (Nasdaq: AGRX) announced participation in several virtual investor conferences in September 2021. Key events include the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, and the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30. Presentations will feature live webcasts available on their Investor Relations website. Agile is focused on women's healthcare with products like the transdermal contraceptive, Twirla.
Agile Therapeutics (Nasdaq: AGRX) has partnered with Pandia Health to launch the first telehealth platform for the Twirla® birth control patch. This collaboration aims to enhance women's access to contraceptive care through online prescriptions and free delivery. Set to phase in Twirla availability in H2 2021, this partnership aligns with the growing trend of telehealth in contraceptive services, especially post-COVID-19. Agile emphasizes its commitment to women's health in this initiative.
Agile Therapeutics (Nasdaq: AGRX) reported significant growth in the second quarter of 2021, with total prescriptions for Twirla increasing by 171% to 5,027. New prescriptions also rose by 103%, driven by a growing number of prescribers exceeding 2,087. The company achieved $1.2 million in net product sales but recorded a net loss of $17.6 million for the quarter. Agile has $31.1 million in cash and options for additional capital through loans and an at-the-market facility. A conference call is scheduled for July 26, 2021.
Agile Therapeutics (Nasdaq: AGRX) will release its second quarter 2021 financial results on July 26, 2021, post-market. A live conference call will occur at 4:30 p.m. EDT, featuring dial-in options for both domestic and international investors. Interested parties can access the live stream and archived webcast through the company's website. Agile Therapeutics focuses on women's healthcare, offering innovative contraceptive solutions, including the non-daily prescription contraceptive, Twirla, utilizing their proprietary Skinfusion® technology.
Agile Therapeutics, a women’s healthcare company, will participate virtually in the William Blair 41st Annual Growth Stock Conference on June 1, 2021, at 10:20 a.m. ET. CEO Al Altomari will lead a fireside chat, which can be accessed live through the Agile Therapeutics website. The webcast will be available for 30 days post-event. Agile Therapeutics is focused on addressing women's healthcare needs, with its primary product being Twirla®, a non-daily transdermal contraceptive system designed for ease of use.
FAQ
What is the current stock price of AGILE THERAPEUTICS (AGRX)?
What is the market cap of AGILE THERAPEUTICS (AGRX)?
What is Agile Therapeutics' primary product?
How well did Agile Therapeutics perform financially in the third quarter of 2023?
What is Skinfusion® technology?
What are the company's future financial projections?
How is the company expanding its market presence?
What are the current trading circumstances of Agile Therapeutics' shares?
How did Agile Therapeutics manage their operational expenses?
What strategic initiatives is Agile Therapeutics currently pursuing?
What impact does the Biden-Harris Administration's new guidance have on Twirla?
Where can more information about Agile Therapeutics be found?
